Literature DB >> 12684753

High frequency of concomitant nm23-H1 and E-cadherin transcriptional inactivation in primary non-inheriting colorectal carcinomas.

George A Garinis1, Evangelos N Manolis, Nick E Spanakis, George P Patrinos, George Peros, Panayiotis G Menounos.   

Abstract

This study evaluated the added significance of nm23-H1 to that of E-cadherin in determining metastatic proclivity in primary sporadic colorectal carcinomas (SCRCs). A clinical cohort of 52 SCRCs was examined for the significance of nm23-H1 and E-cadherin mRNA levels and E-cadherin protein expression levels into the progression of colorectal tumor invasion, determined by their relevance compared with conventional biological markers. A more than twofold decreased expression of nm23-H1 mRNA was reported in 28/52 (54%) of the carcinomas and was positively associated with the presence of nodal metastases and Astler-Coller stages B1 and B2 in 29% and 35% of the SCRCs, respectively. Reduced expression of E-cadherin mRNA was reported in 38.5% of the carcinomas and was similarly associated with stages Astler-Coller B1 and B2 in 27% of the SCRCs. Decreased E-cadherin immunohistochemical expression (grades II and III) was observed in 67% of the samples. E-cadherin mRNA and protein expression were significantly related to each other. The nm23-H1 (+)/E-cadherin (+) coexpression profile was observed in 31% and was significantly related to the absence of lymph node metastases in 31% and stages Astler-Coller B1 and B2 in 29% of the carcinomas examined. Furthermore, the nm23-H1 (-)/E-cadherin (+) coexpression profile was coupled to decreased E-cadherin immunohistochemical protein detection (grade II) in 21% of the cases examined. These findings suggest that impairment of nm23-H1 expression is an early event into the progression of colorectal metastasis that precedes E-cadherin transcriptional silencing in the majority of SCRCs examined. Nm23-H1 may therefore play an important role in suppressing the early steps of metastasis in sporadic cases of colorectal carcinomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12684753     DOI: 10.1007/s00109-003-0420-4

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  28 in total

1.  E-cadherin-catenin: more than a "sticky" molecular complex.

Authors:  B P Wijnhoven; M Pignatelli
Journal:  Lancet       Date:  1999-07-31       Impact factor: 79.321

2.  The NM23 gene maps to human chromosome band 17q22 and shows a restriction fragment length polymorphism with BglII.

Authors:  L Varesco; M A Caligo; P Simi; D M Black; V Nardini; L Casarino; M Rocchi; G Ferrara; E Solomon; G Bevilacqua
Journal:  Genes Chromosomes Cancer       Date:  1992-01       Impact factor: 5.006

Review 3.  Morphogenetic roles of classic cadherins.

Authors:  M Takeichi
Journal:  Curr Opin Cell Biol       Date:  1995-10       Impact factor: 8.382

4.  Hypermethylation-associated transcriptional silencing of E-cadherin in primary sporadic colorectal carcinomas.

Authors:  George A Garinis; Panayiotis G Menounos; Nick E Spanakis; Kostas Papadopoulos; George Karavitis; Ismailou Parassi; Evangelia Christeli; George P Patrinos; Evangelos N Manolis; George Peros
Journal:  J Pathol       Date:  2002-12       Impact factor: 7.996

5.  Reappraisal of the role of NM23-H1 in colorectal cancers.

Authors:  J C Lee; Y J Lin; N H Chow; S T Wang
Journal:  J Surg Oncol       Date:  2001-01       Impact factor: 3.454

6.  Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin.

Authors:  R Heimann; F Lan; R McBride; S Hellman
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

7.  Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer.

Authors:  J M Wheeler; H C Kim; J A Efstathiou; M Ilyas; N J Mortensen; W F Bodmer
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

Review 8.  Disseminated testicular cancer: current chemotherapy strategies.

Authors:  S D Williams; P J Loehrer; C R Nichols; B J Roth; L H Einhorn
Journal:  Semin Oncol       Date:  1989-08       Impact factor: 4.929

9.  Reduced expression of nm23-H1, but not of nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer.

Authors:  Y Tokunaga; T Urano; K Furukawa; H Kondo; T Kanematsu; H Shiku
Journal:  Int J Cancer       Date:  1993-08-19       Impact factor: 7.396

10.  ARF6-GTP recruits Nm23-H1 to facilitate dynamin-mediated endocytosis during adherens junctions disassembly.

Authors:  Felipe Palacios; Jill K Schweitzer; Rita L Boshans; Crislyn D'Souza-Schorey
Journal:  Nat Cell Biol       Date:  2002-12       Impact factor: 28.824

View more
  5 in total

1.  The intratumoral microvessel density and expression of bFGF and nm23-H1 in colorectal cancer.

Authors:  Sahande Elagoz; Reyhan Egilmez; Ayhan Koyuncu; Ahmet Muslehiddinoglu; Sema Arici
Journal:  Pathol Oncol Res       Date:  2006-03-23       Impact factor: 3.201

Review 2.  The role of NM23 in patients with colorectal cancer: A systematic review and meta-analysis.

Authors:  Wei Han; Jun Ma; Fang Cao; Cong Zhang; Rong Zhu; Yong-Wei Hu; Min-Bin Chen; Hou-Zhong Ding
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-02-22

Review 3.  Learning about the functions of NME/NM23: lessons from knockout mice to silencing strategies.

Authors:  Mathieu Boissan; Marie-Lise Lacombe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-12       Impact factor: 3.000

Review 4.  Meta-analysis of histopathological features of primary colorectal cancers that predict lymph node metastases.

Authors:  Sean C Glasgow; Joshua I S Bleier; Lawrence J Burgart; Charles O Finne; Ann C Lowry
Journal:  J Gastrointest Surg       Date:  2012-01-19       Impact factor: 3.452

5.  NDPKA is not just a metastasis suppressor - be aware of its metastasis-promoting role in neuroblastoma.

Authors:  Choon-Yee Tan; Christina L Chang
Journal:  Lab Invest       Date:  2017-10-09       Impact factor: 5.662

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.